Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Articles
  4. Analysis
  5. Vantage Points

Vantage points

Thumbnail
June 25, 2020

Diabetes prevention signal emerges for Farxiga

SGLT2 inhibitors primarily treat diabetes, with benefits also seen in heart and kidney diseases. Might they also help prevent diabetes in the first place?

Thumbnail
March 27, 2019

Should gene therapy patients be asked to pay?

The price in value-based payment deals should by definition be justified, so why is patient cost-sharing part of the calculation? Spark covers this cost, but there is no guarantee that all gene therapy companies will.

Article image
Vantage logo
April 26, 2018

Preventive Alzheimer’s trials keep amyloid hope alive

Drugs have so far failed to make an impact in established Alzheimer's disease, so research is moving towards efforts to prevent the disorder.

Article image
Vantage logo
March 28, 2018

Vertex and orphan drugs test limits of US payers

Vertex's cystic fibrosis drugs are among the most expensive ever evaluated by the US Institute for Clinical and Economic Research.

Article image
Vantage logo
March 15, 2018

Solving the incremental innovation dilemma

Could pricing pressure lead to the end of incremental innovation – and why does this matter?

Article image
Vantage logo
March 06, 2018

As US hospitals consolidate their pharmacy muscles grow

Consolidation of hospital chains could give biopharma another powerful group of payers to contend with.

Article image
Vantage logo
January 23, 2018

Biotech gets creative about the pay cheque

Amid a backlash over the high prices of advanced therapies, biotech companies are coming up with new payment models.

Article image
Vantage logo
October 25, 2017

European approvals face delay from agency move

How the EMA's move out of London could impact European drug approvals.

Vantage logo
October 23, 2017

Vantage Point – Pricing battle shifts to states

Vantage logo
August 21, 2017

Vantage Point – Why generic competition might not stem price moderation calls

Article image
Vantage logo
August 10, 2017

Looking beyond factors in haemophilia

Next-generation projects, including gene therapies, could soon be shaking up the haemophilia market.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.